1. What Is the Nuclear Medicine Market?
The Nuclear Medicine Market covers the diagnostic imaging using radiopharmaceuticals including SPECT and PET imaging and the therapeutic use of radiopharmaceuticals for targeted radionuclide therapy. The market also covers the production, distribution, and quality control infrastructure for the radionuclides and radiopharmaceuticals. Nuclear medicine depends on these for both diagnostic and therapeutic applications across oncology, cardiology, neurology, and endocrinology. SPECT imaging using technetium-99m labelled radiopharmaceuticals for myocardial perfusion imaging, bone scan, and thyroid scintigraphy dominates the diagnostic nuclear medicine volume globally. The dominance comes from the excellent gamma camera availability and the generator-based on-site Tc-99m production. The on-site production makes technetium the workhorse radionuclide for most nuclear medicine departments. Theranostics pairs the diagnostic radiopharmaceutical that images the target with the therapeutic radiopharmaceutical that delivers the cytotoxic radiation dose to the same molecular target. The approach represents the fastest-growing area of nuclear medicine. The PSMA-targeted Lu-177 therapy for metastatic castration-resistant prostate cancer and the SSTR-targeted Lu-177 dotatate therapy for gastroenteropancreatic neuroendocrine tumours establish the theranostic concept in FDA-approved therapies. The nuclear medicine supply chain spans the SPECT/PET camera hardware, the radiopharmaceutical manufacturing, and the distribution infrastructure. Hospital nuclear medicine departments depend on the isotope supply that must arrive within the radioactive half-life that makes nuclear medicine uniquely time-critical.
2. Nuclear Medicine Market Size & Forecast
3. Emerging Technologies
- Lu-177 PSMA therapy approval as Pluvicto by Novartis for metastatic castration-resistant prostate cancer demonstrated 7.7-month improvement in radiographic progression-free survival versus standard of care. The approval has established targeted radionuclide therapy as a major new therapeutic modality in oncology. The clinical demand for PSMA and other theranostic therapies drives the Novartis and GE HealthCare radionuclide therapy manufacturing capacity expansion.
- Technetium-99m supply security concerns arise from the aging global Mo-99 production reactor infrastructure concentrated at a small number of research reactors in Netherlands, Belgium, and Canada. The concerns have driven investment in the cyclotron-based Tc-99m production directly from Mo-100 targets. The reactor-independent alternative provides geographic diversification of the global Tc-99m supply that nuclear medicine cannot function without.
- Alpha particle emitting radiopharmaceutical development uses actinium-225 that delivers dense ionisation along short particle tracks enabling the targeted killing of single tumour cells. The development has advanced with actinium-225 labelled PSMA compounds in clinical trials. The compounds demonstrate the next theranostic generation beyond the beta emitter Lu-177 that current FDA-approved therapies use.
- Digital SPECT with CZT cadmium zinc telluride semiconductor detector replaces conventional NaI scintillator gamma camera technology in the Siemens Symbia Intevo Bold and GE StarGuide. The detector provides the improved energy resolution, higher count rate capability, and reduced acquisition time. The CZT solid-state detectors achieve these over conventional scintillator-PMT gamma cameras.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Molecular Imaging Market.
4. Key Market Opportunity
Substantial growth potential in the Nuclear Medicine market is Pluvicto and theranostic radioligand therapy capacity expansion, where manufacturing scale-up addresses the supply constraints limiting patient access. Novartis capturing growing Pluvicto prescribing reflects this demand-supply gap opportunity. A parallel growth driver is driven by actinium-225 targeted alpha therapy development. As Pluvicto capacity expands and TAT programmes advance, the addressable opportunity is growing from supply-limited theranostic use toward full demand satisfaction and next-generation alpha therapy.
5. Top Companies in the Nuclear Medicine Market
The following organisations hold leading positions in the Nuclear Medicine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- GE HealthCare
- Siemens Healthineers
- Philips
- Canon
- Bracco Imaging
- Lantheus
- Curium Pharma
- Cardinal Health
- Jubilant Radiopharma
- Bayer
- Novartis
- Eckert and Ziegler
- Telix Pharmaceuticals
6. Market Segmentation
The Nuclear Medicine Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Type | Diagnostic SPECTDiagnostic PETTherapeutic RLT |
| By Radionuclide | Technetium-99mLutetium-177Gallium-68Actinium-225 |
| By Application | OncologyCardiologyNeurology |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Nuclear Medicine Market trajectory over the forecast period:
Lu-177 PSMA Therapy Pluvicto Demonstrating 7.7-Month Radiographic PFS Improvement Has Established Targeted Radionuclide Theranostics as a Major Oncology Modality and Driven Manufacturing Capacity Expansion for the Growing Therapy Pipeline.Siemens Healthineers' Biograph Vision, GE Healthcare's Discovery MI, and Philips' Vereos PET-CT represent the digital PET-CT platforms that cancer centres deploy for FDG-PET staging of lung, colorectal, lymphoma, and other cancers where combined metabolic and anatomical imaging guides staging decisions, surgical planning, and radiation therapy target definition. The digital PET detector technology using silicon photomultipliers replacing photomultiplier tubes has improved PET sensitivity and timing resolution, enabling image quality improvements that reduce scan time, patient dose, and PET dose requirements that the sensitivity improvement allows. The whole-body cancer staging PET-CT examination providing TNM staging information from a single scan session has replaced the sequential CT, bone scan, and nuclear medicine studies that multi-modality staging previously required, reducing the time and cost of diagnostic workup that treatment planning depends upon.
Cyclotron-Based Tc-99m Production From Mo-100 Targets Is Providing the Reactor-Independent Supply Alternative That Diversifies the Single-Point-of-Failure Risk in the Aging Research Reactor Infrastructure That Nuclear Medicine Depends Upon.The FDA approval of Ga-68 PSMA-11 and F-18 DCFPyL for prostate cancer PET imaging and the EMA approval of multiple PSMA PET tracers has enabled clinical adoption for biochemically recurrent prostate cancer evaluation where the PSA rise after surgery or radiation requires the sensitive disease localisation that PSMA PET provides with superior sensitivity and specificity. Lantheus Holdings' PYLARIFY and AAA-Novartis' Illuccix provide the commercially distributed PSMA PET radiopharmaceuticals that nuclear medicine departments use without on-site cyclotron or generator infrastructure. The theranostic extension of PSMA imaging where PSMA-targeted lutetium-177 therapy from Novartis treats metastatic prostate cancer in patients whose tumours show adequate PSMA expression on PET imaging has created the first companion diagnostic-therapy pair in prostate cancer.
CZT Semiconductor Detector Digital SPECT Replacing Scintillator-PMT Gamma Cameras Is Delivering Improved Energy Resolution and Reduced Acquisition Time That Elevate Cardiac SPECT Image Quality While Reducing Radiation Dose.Advanced Accelerator Applications' Lutathera for SSTR-expressing neuroendocrine tumours and Novartis' Pluvicto for PSMA-positive prostate cancer represent the approved theranostic therapy products that use the same molecular targeting for both imaging and therapeutic radioisotope to select the patients most likely to respond to targeted radionuclide therapy. The radiopharmaceutical manufacturing and supply chain for clinical theranostics requires GMP-compliant lutetium-177 and gallium-68 production and kit preparation that supports multi-dose clinical supply at the radiopharmacy and hospital level. The emerging PSMA-targeted actinium-225 alpha particle therapy from Fusion Pharmaceuticals and RadioMedix and FAPi fibroblast activation protein imaging and therapy approaches demonstrate the expanding theranostic target development pipeline that nuclear medicine's diagnostic capability is enabling across multiple cancer types.
For related market intelligence, see the Pet Scan Market.
8. Segmental Analysis
By type, the therapeutic radionuclide segment dominated the Nuclear Medicine Market in 2025, as Novartis Pluvicto and Lutathera anchored lutetium-based targeted radiotherapy across prostate and neuroendocrine cancers, generating the fastest-rising revenue in the nuclear medicine category.
By radionuclide, the actinium and targeted alpha therapy segment is projected to register the highest growth rate through 2034, as Eli Lilly, AstraZeneca, and Bristol-Myers Squibb advance actinium-225 programmes that deliver higher-energy targeted radiation to tumour cells in patients who have exhausted approved lutetium-based options.
9. Regional Analysis
Regional demand patterns across the Nuclear Medicine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Nuclear Medicine Market in 2025, accounting for approximately 48% of global revenue, due to US premium pricing for Pluvicto, Lutathera, and diagnostic radiopharmaceuticals and the large nuclear medicine infrastructure. Moreover, Pluvicto prescribing and TAT clinical development are most advanced in the US. In addition, PSMA and DOTATATE diagnostics are established. Regional dominance is attributed to this combination of pricing environment and theranostics leadership.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Nuclear Medicine Market through 2034, driven by expanding Pluvicto and Lutathera access across European healthcare systems and the active European clinical trial network in radioligand therapy and TAT programmes. The region is also witnessing actinium-225 TAT development. Moreover, theranostics centre infrastructure is expanding. The combination of these demand drivers and clinical network positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Nuclear Medicine Market was valued at USD 5.77 Bn in 2025 and is projected to reach USD 13.37 Bn by 2034, growing at a CAGR of 9.8% over the 2026–2034 forecast period.
The Nuclear Medicine Market is projected to grow at a CAGR of 9.8% from 2026 to 2034.
North America dominated the Nuclear Medicine Market in 2025, accounting for approximately 48% of global revenue, due to US premium pricing for Pluvicto, Lutathera, and diagnostic radiopharmaceuticals and the large nuclear medicine infrastructure.
The leading companies in the Nuclear Medicine Market include GE HealthCare, Siemens Healthineers, Philips, Canon, Bracco Imaging, Lantheus, Curium Pharma, Cardinal Health, Jubilant Radiopharma, Bayer, Novartis, Eckert and Ziegler, Telix Pharmaceuticals.
Lu-177 psma therapy pluvicto demonstrating 7.7-month radiographic pfs improvement has established targeted radionuclide theranostics as a major oncology modality and driven manufacturing capacity expansion for the growing therapy pipeline.
By type, the therapeutic radionuclide segment dominated the Nuclear Medicine Market in 2025, as Novartis Pluvicto and Lutathera anchored lutetium-based targeted radiotherapy across prostate and neuroendocrine cancers, generating the fastest-rising revenue in the nuclear medicine category.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.